Former director at Illumina Inc
- Recent developments around Illumina’s (NASDAQ: ILMN) acquisition of Grail, including outlook, potential integration challenges and liquid biopsy opportunity
- Sequencing industry trends and competitive landscape, including Pacific Biosciences (NASDAQ: PACB) and Oxford Nanopore
- Illumina's expansion into clinical genomics and recent partnership with SomaLogic (NASDAQ: SLGC) to expand in proteomic solutions
- 2022 outlook – growth expectations, strategic assessments and AGBT (Advances in Genome Biology and Technology) General Meeting
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.